Does Ipamorelin Raise Cortisol or Prolactin? What Studies Show

    Does Ipamorelin Raise Cortisol or Prolactin? What Studies Show

    Ipamorelin didn't raise cortisol in a 1998 pig study, but human data are missing. Why the prolactin claim is overstated, GHRP-6 compared, FDA status.

    Written by Dr. Andrii Kaleniuk. Updated November 17, 2026.

    Ipamorelin did not raise cortisol in the original 1998 study that tested it, but that finding came from pigs, not people, and we found no published human study that measured ipamorelin's effect on cortisol or prolactin. Ipamorelin is a small lab-made peptide (a chain of five amino acids) that prompts the pituitary gland to release growth hormone (GH). Cortisol is the body's main stress hormone, and prolactin is a pituitary hormone best known for milk production, which in men can affect libido when it is high. Older peptides in the same family, GHRP-2 and GHRP-6, can raise both hormones in humans. The claim that ipamorelin is "selective" rests largely on one Novo Nordisk study in rats and pigs, and in that study none of the peptides tested, including GHRP-6, changed prolactin, so the prolactin contrast is weaker than many websites suggest. Ipamorelin is not approved by the US Food and Drug Administration (FDA) for any use. This article explains what the studies measured, what they did not, and what remains unknown.

    Does Ipamorelin Raise Cortisol or Prolactin? The Short Answer

    1. 1Cortisol: in conscious pigs, ipamorelin did not raise ACTH or cortisol, while GHRP-2 and GHRP-6 did (Raun, 1998).
    2. 2Prolactin: in the same pig study, no peptide tested changed prolactin, so it does not show ipamorelin is better than GHRP-6 on prolactin.
    3. 3Humans: the human pharmacokinetic study abstract reported growth hormone only; we found no human cortisol or prolactin data.
    4. 4Older peptides: in humans, GHRP-6, GHRP-2 and hexarelin raised cortisol and prolactin in separate studies.
    5. 5Patient trials: the only published trial, in bowel surgery recovery, missed its main goal and reported no hormone results.
    6. 6Regulation: not FDA-approved; on FDA's Category 2 list for compounding safety concerns; banned in sport by WADA.

    Why Do Cortisol and Prolactin Matter With GH Peptides?

    Ipamorelin, GHRP-2 and GHRP-6 all act on the ghrelin receptor (also called the GH secretagogue receptor), the same receptor used by the hunger hormone ghrelin. Stimulating this receptor releases GH from the pituitary, but with older peptides it can also activate the stress hormone system, known as the HPA axis, raising ACTH (the pituitary signal that drives the adrenal glands) and then cortisol. Some also raised prolactin. Persistently high cortisol can affect blood sugar, sleep and body composition, and high prolactin can affect libido and sexual function. That is why "no cortisol, no prolactin" became the selling point for ipamorelin. Background on the peptide is in what is ipamorelin.

    What Did the 1998 Raun Study Test?

    The study, by Kirsten Raun and colleagues at Novo Nordisk, was published in the European Journal of Endocrinology in 1998 under the title "Ipamorelin, the first selective growth hormone secretagogue." It tested ipamorelin in three settings. In rat pituitary cells grown in the lab, ipamorelin released GH with potency and efficacy similar to GHRP-6. In anaesthetised rats, it again had broadly similar potency to GHRP-6. The key hormone tests were done in conscious pigs (swine), where the researchers compared ipamorelin with GHRP-6, GHRP-2 and GHRH, the body's own GH-releasing hormone. We could read only the abstract, so details such as the number of pigs are not available to us.

    Did Ipamorelin Raise Cortisol in That Study?

    No, not in pigs. GHRP-6 and GHRP-2 raised plasma ACTH and cortisol in the swine. Ipamorelin did not: its ACTH and cortisol levels were not significantly different from those after GHRH, which does not activate the stress axis, even at amounts more than 200 times higher than the level needed for half its maximum GH effect. The authors concluded that ipamorelin was the first ghrelin-receptor agonist with GH selectivity similar to GHRH.

    That is a meaningful animal result, but it has limits. Pigs and humans differ in how their hormone systems respond, the study tested short-term responses rather than repeated use, and it was run by the company developing the drug. It shows ipamorelin was selective in pigs; it does not show the same in people.

    Does Ipamorelin Raise Prolactin?

    We do not know in humans, and the pig study does not settle it. In the Raun swine experiments, none of the secretagogues tested affected prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH) or thyroid-stimulating hormone (TSH). That includes GHRP-6 and GHRP-2. So the study found no prolactin difference between ipamorelin and GHRP-6 at all. Websites that say ipamorelin "avoids the prolactin rise of GHRP-6" are relying on human studies of GHRP-6, not on any direct comparison with ipamorelin. Common reported side effects are reviewed in ipamorelin side effects.

    Do GHRP-2 and GHRP-6 Raise Cortisol and Prolactin in Humans?

    Yes, in separate human studies. In 1990, Cyril Bowers and colleagues gave the GHRP-6 hexapeptide to healthy men in the Journal of Clinical Endocrinology and Metabolism. GH rose with the dose, and prolactin and cortisol roughly doubled, but only at the highest dose tested; LH and TSH did not change. In 1997, Emanuela Arvat, Ezio Ghigo and colleagues reported in Peptides that GHRP-2 and hexarelin raised prolactin in humans (less than the hormone TRH did) and raised ACTH and cortisol about as much as the stress-axis hormone hCRH. They concluded that these peptides are "not fully specific."

    Cortisol and prolactin findings by peptide and species

    Compound
    Species
    ACTH or cortisol
    Prolactin
    Source

    Ipamorelin

    Pigs

    No significant rise (similar to GHRH)

    No change

    Raun 1998

    GHRP-6

    Pigs

    Increased

    No change

    Raun 1998

    GHRP-2

    Pigs

    Increased

    No change

    Raun 1998

    GHRP-6

    Healthy men

    Cortisol roughly doubled at the highest dose only

    Roughly doubled at the highest dose only

    Bowers 1990

    GHRP-2 and hexarelin

    Humans

    ACTH and cortisol rose, similar to hCRH

    Rose, less than TRH

    Arvat 1997

    Ipamorelin

    Healthy men

    Not reported in abstract

    Not reported in abstract

    Gobburu 1999

    The table shows the gap: the human comparisons come from older peptides, while the ipamorelin selectivity data come from pigs. How ipamorelin compares with other GH-releasing compounds is covered in sermorelin vs ipamorelin and tesamorelin vs ipamorelin.

    What Did the Human Pharmacokinetic Study Measure?

    The only human study of ipamorelin's basic behavior we found is by Jogarao Gobburu and colleagues, published in Pharmaceutical Research in 1999. Healthy men, eight per group, received five escalating short intravenous infusions. Ipamorelin was cleared from the blood with a half-life of about 2 hours, and blood levels rose in proportion to the amount given. Each infusion produced a single GH pulse peaking at about 40 minutes and then fading to negligible levels, and people varied more in their GH response than in their blood levels of the drug. The abstract reports no cortisol, prolactin or ACTH results. The full text may contain them, but we could not access it, so we cannot say whether they were measured.

    What Happened in the Postoperative Ileus Trials?

    Ipamorelin's only patient trials were for postoperative ileus, a temporary stall of the bowel after abdominal surgery, sponsored by the drug company Helsinn. In the published phase 2 trial (Beck and colleagues, International Journal of Colorectal Disease, 2014), 117 bowel surgery patients were enrolled and 114 analyzed; they received intravenous ipamorelin or placebo for up to 7 days. The main goal, time until patients could tolerate a solid meal, was 25.3 hours on ipamorelin vs 32.6 hours on placebo, a difference that was not statistically significant (p=0.15). Side effects of any kind were reported by 87.5% on ipamorelin and 94.8% on placebo, and the authors called it well tolerated.

    A second, larger phase 2 trial (NCT01280344, 320 patients, 2011 to 2014) was completed, but we found no published results. A 2016 meta-analysis of five trials of ghrelin-receptor drugs found no apparent effect on ileus. None of the sources we accessed reported cortisol or prolactin outcomes from these trials.

    Ipamorelin patient trials

    Trial
    Number
    Design
    Primary result
    Hormone data reported

    Beck et al. 2014 (NCT00672074)

    117 enrolled, 114 analyzed

    Phase 2, double-blind, placebo-controlled, IV, up to 7 days

    25.3 h vs 32.6 h to solid meal; p=0.15, not significant

    None found

    NCT01280344

    320

    Phase 2, ipamorelin vs saline, completed 2014

    No published results found

    None found

    Is Ipamorelin FDA Approved or Legal to Use?

    Ipamorelin is not FDA-approved for any condition. FDA added ipamorelin acetate to Category 2 of its bulk drug substances list for 503B outsourcing facilities on September 29, 2023, citing possible immunogenicity (the risk of an immune reaction) and "serious adverse events including death when ipamorelin was administered intravenously." FDA said it lacks sufficient information on other injectable routes. When FDA removed seven other peptides, including BPC-157 and TB-500, from Category 2 in April 2026, ipamorelin was not among them. We could not find which events or trial FDA was referring to, or whether the drug caused them. The broader picture is in FDA peptide rules in 2026, and the UK position is in is ipamorelin legal in the UK.

    For athletes, ipamorelin is prohibited at all times by the World Anti-Doping Agency (WADA) under class S2.2, as listed by Sport Integrity Australia; see peptides banned by WADA. Products sold online as "research use only" are not made to drug standards, and their purity and content are unverified, as explained in research use only peptides.

    What Remains Unknown About Ipamorelin and Hormones?

    1. 1Human hormone data: no published study we found measured cortisol, prolactin or ACTH in people after ipamorelin.
    2. 2Repeated use: all hormone data come from single or short-term exposures.
    3. 3Women and older adults: the human pharmacokinetic study enrolled healthy men only.
    4. 4Hunger: often attributed to GHRP-6, but we found no human data on ipamorelin and appetite.
    5. 5Unregulated products: purity, dose accuracy and contamination are unknown for products sold online.
    6. 6Long-term safety: no long-term human safety data exist, and FDA has flagged serious safety concerns.

    Combination products raise further unknowns, discussed in CJC-1295 and ipamorelin side effects, and claims about muscle and recovery are reviewed in ipamorelin for bodybuilding.

    When to Talk to Your Doctor

    1. 1If you are considering any GH-releasing peptide, including ipamorelin.
    2. 2If you have used ipamorelin and notice breast tenderness or discharge, low libido, unusual fatigue or swelling.
    3. 3If you have diabetes or high blood sugar, since GH and cortisol both affect glucose.
    4. 4If you have a pituitary, adrenal or thyroid condition, or a history of cancer.
    5. 5If you are a tested athlete, before using any supplement or peptide.

    What to Do Next: Questions to Ask Your Doctor

    1. 1Is there an approved treatment for the goal I have in mind?
    2. 2Should my cortisol, prolactin, IGF-1 or blood sugar be checked?
    3. 3What are the risks of using an unapproved peptide of unknown purity?
    4. 4Could any symptoms I have be caused by a hormone imbalance?
    5. 5How would this affect drug testing in my sport?

    The Bottom Line

    The idea that ipamorelin raises GH without raising cortisol comes from a 1998 company study in pigs, where it did not raise ACTH or cortisol while GHRP-2 and GHRP-6 did. The prolactin claim is weaker: in that study no peptide changed prolactin. Human data are thin, with one small pharmacokinetic study in men that reported GH only and surgical trials that reported no hormone results. Ipamorelin is not FDA-approved, FDA has flagged safety concerns, and it is banned in sport.

    FAQ

    In pigs, ipamorelin did not raise cortisol or ACTH, unlike GHRP-2 and GHRP-6 (Raun, 1998). We found no published human study that measured cortisol after ipamorelin.

    Human data are lacking. In the 1998 pig study, no peptide tested, including GHRP-6, changed prolactin, so it does not show ipamorelin is better than GHRP-6 on prolactin.

    In humans, GHRP-6 raised cortisol and prolactin at the highest dose tested. Ipamorelin avoided the cortisol rise in pigs, but direct human comparisons have not been published.

    In pigs, it released GH without raising ACTH or cortisol, which is why it was called selective. Whether that holds in humans has not been shown in published studies.

    No. It is not approved for any use, and FDA lists ipamorelin acetate in Category 2 for compounding because of safety concerns.

    Hunger is often linked to GHRP-6, but we found no human data on ipamorelin and appetite.

    Sources

    This article summarizes published research for general information and is not medical advice. Ipamorelin is not approved for human use. The 1998 selectivity study was conducted by Novo Nordisk, and the ileus trials were sponsored by Helsinn.

    Dr. Andrii Kaleniuk

    Author

    Published November 17, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    CJC-1295 + Ipamorelin for Muscle Growth: Real Gains or Just GH Hype?